Abvc Biopharma Inc Reports Results For The Quarter Ended In March: Earnings Summary

ABVC Biopharma

15/08/2022 23:43

* ABVC Biopharma Inc  ABVC.OQ  reported a quarterly adjusted
loss
of 6 cents​​ per share for the quarter ended in March. The lone
analyst forecast for the quarter was for a loss of 20 cents per
share.
    * Revenue rose 18.9% to $313.00 thousand from a year ago;
analysts
expected $26.00 thousand. 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * ABVC Biopharma Inc shares had fallen by 36.8% this
quarter and
lost 80.2% so far this year.
    * Wall Street's median 12-month price target for ABVC
Biopharma
Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 15
at 10:43 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2022      -0.20          -0.06          Beat
 Dec. 31 2021      -0.04          -0.31          Missed
 Sep. 30 2021      -0.04          -0.07          Missed